Results 131 to 140 of about 65,998 (238)

Nivolumab Enhances the Cytotoxicity of Chemotherapeutic Agents in A549 Lung Adenocarcinoma Cell Lines. [PDF]

Curr Issues Mol Biol
Okşak N, Karhan O.
europepmc   +1 more source

Genomic Evolution and Immune Contexture With Therapeutic Relevance in Pancreatic Neuroendocrine Neoplasms

Cancer Science, EarlyView.
Lineage‐dependent immunogenomic landscapes and biologically informed therapy in pancreatic neuroendocrine neoplasms. Pancreatic neuroendocrine neoplasms display lineage‐dependent immunogenomic landscapes, in which genomic alterations, epigenetic states, antigen‐presentation status, immune‐cell infiltration, and suppressive microenvironments co‐evolve ...
Yohei Tabe, Eito Nakagawa, Daisuke Asano, Eriko Katsuta, Daisuke Ban, Shogo Kumagai   +5 more
wiley   +1 more source

Pathological Complete Response to Nivolumab Plus Ipilimumab Combination Therapy in Advanced Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus. [PDF]

IJU Case Rep
Tsuchiya T, Kimura G, Takeda H, Akatsuka J, Hasegawa H, Toyama Y, Sakatani T, Shimizu A, Ohashi R, Kondo Y.   +9 more
europepmc   +1 more source

Immunological Heterogeneity in Gastric Cancer: Context‐Dependent Role of CD8+ T Cells

Cancer Science, EarlyView.
CD8+ T cell infiltration in gastric cancer shows subtype‐dependent prognostic and predictive significance across TCGA molecular subtypes. Its clinical value is context‐dependent and requires integrated immune profiling to guide modern chemoimmunotherapy strategies.
Xiaofei Sun, Zihao Yang, Hongtao Qu, Jinhui Wu   +3 more
wiley   +1 more source

Early Progressive Disease During Nivolumab Plus Ipilimumab Therapy Predicts Poor Survival in Japanese Patients with Advanced Renal Cell Carcinoma: A Single-Center 12-Week Landmark Study. [PDF]

Res Rep Urol
Furubayashi N, Tsujita J, Takayama A, Shiraishi Y, Nakamura M, Negishi T.   +5 more
europepmc   +1 more source

Clinical and Imaging Features of Tepotinib‐Induced Interstitial Lung Disease in the Post‐Marketing Setting in Japan

Cancer Science, EarlyView.
This article reports on the clinical and imaging features of tepotinib‐induced interstitial lung disease (ILD), which were evaluated by an ILD adjudication committee composed of external respiratory and radiology experts, and the committee expertly identified 35 patients with tepotinib‐induced ILD from spontaneous adverse event reports accumulated in ...
Terufumi Kato, Tomohisa Baba, Masahiro Endo, Shehla Endo, Eisuke Horii, Masahiko Kusumoto   +5 more
wiley   +1 more source

From Tumour to Bloodstream: Advancing PD‐L1 Testing With Liquid Biopsies in Non‐Small Cell Lung Cancer

Cytopathology, EarlyView.
This review explores liquid biopsy as a complementary approach to tissue‐based PD‐L1 assessment in advanced NSCLC treated with immune checkpoint inhibitors. Focusing on circulating tumour cells, extracellular vesicles, and circulating tumour DNA, it summarises current evidence, technical challenges, and future perspectives for personalised ...
R. Leporati, V. Callegari, A. Ancora, M. Palmieri, B. Riccò, E. Cabitza, L. Trudu, K. Di Emidio, C. Chiavelli, A. Eccher, I. Mastrolia, V. Catani, S. Bettelli, G. Guaitoli, M. Dominici, F. Bertolini   +15 more
wiley   +1 more source

Lectin-captured plasma microRNAs predict response and survival in patients with non-small cell lung cancer treated with nivolumab. [PDF]

Oncol Lett
Narusawa E, Nakano Y, Nakazawa S, Hori K, Ohtaki Y, Kawatani N, Yazawa T, Yoshikawa R, Numajiri K, Kuriyama R, Kurokawa H, Taguchi Y, Mostafavi Zadeh SM, Okami H, Shiraishi T, Nakazawa N, Igarashi T, Kaira K, Saeki H, Shirabe K, Yokobori T.   +20 more
europepmc   +1 more source

Significant Response to Nivolumab Plus Ipilimumab in Metastatic Mucinous Tubular and Spindle Cell Carcinoma: A Case Report. [PDF]

IJU Case Rep
Shimasaki S, Yamamoto S, Iguchi M, Yamashita E, Atagi K, Shiba Y, Fukata S, Satake H, Karashima T, Inoue K.   +9 more
europepmc   +1 more source

Incidence, severity and potential pathomechanism of immune‐related pruritus in melanoma patients undergoing immune checkpoint inhibitor therapy

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Pruritus is a frequent cutaneous immune‐related adverse event (irAE) associated with immune checkpoint inhibitors (ICI), impacting patients' quality of life. This study investigates the incidence, severity and management of pruritus in melanoma patients treated with ICI.
Andrea Roggo, Nikolina Ivanovic, Patrick Turko, Lukas Kraehenbuehl, Mitchell Levesque, Reinhard Dummer, Barbara Meier‐Schiesser   +6 more
wiley   +1 more source